title: Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia.
abstract: OBJECTIVE
  To quantify the isoprostane 8,12-iso-iPF2alpha-VI in brain tissues obtained from patients with AD, patients with frontotemporal dementia (FTD), and controls.
  
  
  BACKGROUND
  Enhanced brain oxidative stress with secondary damage to cellular macromolecules may play a role in the pathogenesis of AD and FTD. The isoprostane 8,12-iso-iPF2alpha-VI is a specific and sensitive marker of in vivo lipid peroxidation and is increased in AD.
  
  
  METHODS
  Levels of this isoprostane were determined by gas chromatography/negative ion chemical ionization mass spectrometry.
  
  
  RESULTS
  Levels of 8,12-iso-iPF2alpha-VI were markedly elevated in both frontal and temporal cortex of AD brains compared to the corresponding areas of FTD and controls. No significant difference in brain 8,12-iso-iPF2alpha-VI levels for any regions considered was observed between FTD and controls.
  
  
  CONCLUSIONS
  Lipid peroxidation is a feature of AD, but not FTD. The generation of 8,12-iso-iPF(2alpha)-VI in the brain is not a general or final common pathway of neurodegeneration, but may be relatively specific for disease processes in AD and not FTD.
authors.affiliation: Center for Experimental Therapeutics, Department of Pharmacology, University of Pennsylvania, School of Medicine, Philadelphia 19104, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Yao
authors.forename: V
authors.initials: V
authors.lastname: Zhukareva
authors.forename: S
authors.initials: S
authors.lastname: Sung
authors.forename: C M
authors.initials: CM
authors.lastname: Clark
authors.forename: J
authors.initials: J
authors.lastname: Rokach
authors.forename: V M-Y
authors.initials: VM
authors.lastname: Lee
authors.forename: J Q
authors.initials: JQ
authors.lastname: Trojanowski
authors.forename: D
authors.initials: D
authors.lastname: Praticò
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology; D015415:Biomarkers; D001923:Brain Chemistry; D003704:Dementia / Q000145:classification / Q000378:metabolism* / Q000473:pathology; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000032:analysis*; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D015227:Lipid Peroxidation; D008297:Male; D008875:Middle Aged; D009410:Nerve Degeneration; D018384:Oxidative Stress; D010300:Parkinson Disease / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D020774:Pick Disease of the Brain / Q000378:metabolism / Q000473:pathology; D013494:Supranuclear Palsy, Progressive / Q000378:metabolism / Q000473:pathology
chemical_list: C115626:8,12-iso-isoprostane F2alpha-VI; D015415:Biomarkers; D015237:Dinoprost